Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Specimen Handling 71Magnetic Resonance Spectroscopy 55Biopsy 43pembrolizumab 25Carboplatin 25Radiation 24Radiotherapy 23Cyclophosphamide 23Nivolumab 21Paclitaxel 20Cisplatin 20olaparib 18Etoposide 18Doxorubicin 17X-Rays 16Vincristine 16Taxes 15Immunoglobulin G 15Disulfides 15Radiotherapy, Intensity-Modulated 14Leucovorin 14Dexamethasone 14Cytarabine 14Bevacizumab 14durvalumab 13Prednisone 13Platinum 131,2-diaminocyclohexaneplatinum II citrate 13Methotrexate 11Ipilimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × exemestane × 30 days × Clear all
NCT01272037 2026-06-03

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
5,018 enrolled 14 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT00310180 2026-05-29

TAILORx

National Cancer Institute (NCI)

Phase 3 Active not recruiting
10,273 enrolled 14 charts
Breast

Breast Neoplasms

NCT02115282 2026-05-29

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

National Cancer Institute (NCI)

Phase 3 Active not recruiting
608 enrolled 18 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡